Helen Varsos

Johnson & Johnson (United States) — United States

Medicine · Health Sciences

12h-index818citations50works1.92yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(35), Multiple Myeloma Research and Treatments(28), Biosimilars and Bioanalytical Methods(11), Protein Degradation and Inhibitors(10), Chronic Myeloid Leukemia Treatments(4)

Publications50 total

Clinical experience with cranial nerve palsy in patients infused with ciltacabtagene autoleucel for the treatment of relapsed/refractory MM in CARTITUDE-1, -2, and -4
Blood Cancer Journal·2025Open Access
Efficacy/Safety of Cilta-Cel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline ASCT: Updated Follow-Up From CARTITUDE-2 Cohort D
Clinical Lymphoma Myeloma & Leukemia·2025
P-010 Efficacy/Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Patients With Multiple Myeloma Who Had Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Clinical Lymphoma Myeloma & Leukemia·2024
Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Clinical Lymphoma Myeloma & Leukemia·2024
MM-505 Efficacy and Safety of Ciltacabtagene Autoleucel ± Lenalidomide Maintenance in Newly Diagnosed Multiple Myeloma With Suboptimal Response to Frontline Autologous Stem Cell Transplant: CARTITUDE-2 Cohort D
Clinical Lymphoma Myeloma & Leukemia·2024
Efficacy and safety of ciltacabtagene autoleucel ± lenalidomide maintenance in newly diagnosed multiple myeloma with suboptimal response to frontline autologous stem cell transplant: CARTITUDE-2 cohort D.
Journal of Clinical Oncology·2024· 6 cited
Ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma: CARTITUDE-2 cohort A expansion subgroup.
Journal of Clinical Oncology·2024
PCR134 Psychometric Properties of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in Patients with Relapsed/Refractory Multiple Myeloma (MM): Analysis of Phase 2 CARTITUDE-2 Study Cohorts A, B, and C
Value in Health·2024Open Access
Clinical Experience with Cranial Nerve Impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)
Transplantation and Cellular Therapy·2024· 8 cited
The Phase 2 Cartitude-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1–3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
Transplantation and Cellular Therapy·2024· 5 cited
The Phase 2 CARTITUDE-2 Trial: Updated Efficacy and Safety of Ciltacabtagene Autoleucel in Patients with Multiple Myeloma and 1-3 Prior Lines of Therapy (Cohort A) and with Early Relapse after First Line Treatment (Cohort B)
Blood·2023· 27 cited
Clinical Experience with Cranial Nerve Impairment in the CARTITUDE-1, CARTITUDE-2 Cohorts A, B, and C, and Cartitude-4 Studies of Ciltacabtagene Autoleucel (Cilta-cel)
Blood·2023· 14 cited
P-240 Efficacy and safety of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma and prior noncellular anti-BCMA therapy: CARTITUDE-2 cohort C
Clinical Lymphoma Myeloma & Leukemia·2023
B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
HemaSphere·2023· 1 citedOpen Access
P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
HemaSphere·2023Open Access
Cilta-Cel Efficacy and Safety in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
Transplantation and Cellular Therapy·2023Open Access
Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up
Blood·2022· 25 cited
Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy
Blood·2022· 2 cited
MM-183 CARTITUDE-2 Cohort A: Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel) in Lenalidomide-Refractory Patients With Progressive Multiple Myeloma (MM) After 1–3 Prior Lines of Therapy (LOT)
Clinical Lymphoma Myeloma & Leukemia·2022· 6 cited
MM-153 Phase 2 CARTITUDE-2 Study (Cohort B): Updated Clinical Data and Biological Correlative Analyses of Ciltacabtagene Autoleucel (cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients With Multiple Myeloma (MM) and Early Relapse After Initial Therapy
Clinical Lymphoma Myeloma & Leukemia·2022· 1 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Kevin C. De Braganca(37), Jordan M. Schecter(36), Christina Corsale(33), Yaël C. Cohen(31), Adam D. Cohen(29), Muhammad Akram(28), Pankaj Mistry(25), Niels W.C.J. van de Donk(24), Hermann Einsele(22), Lida Pacaud(21), Tonia Nesheiwat(21), Enrique Zudaire(20), Tito Roccia(20), Mounzer Agha(19), Deepu Madduri(16), Dong Geng(15), Tessa Kerre(15), Wilfried Roeloffzen(15), Michel Delforge(14), Muhammad Akram(14)